The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.

开始日期2024-09-01

申办/合作机构

TRIO Fertility, Inc.初创企业

NCT06450301 / RecruitingN/A

Is Thin Endometrial Lining Associated With Senescent Endometrial Cells

The goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives. The main question it aims to answer is:
Are there any senescent cells present in thin endometrial lining?
During the luteal phase of the cycle, participants will will undergo:
* Gynecologic US to measure the endometrial lining thickness and pattern.
* Endometrial biopsy with Pipelle catheter

开始日期2024-09-01

申办/合作机构

TRIO Fertility, Inc.初创企业

NCT06117982 / Recruiting临床2期

Does Subcutaneous Granulocyte Colony Stimulating Factor (G-CSF) Improve Ovarian Reserve in Women With Premature Ovarian Insufficiency?

The goal of this pilot study is to improve ovarian reserve markers in patients with premature ovarian insufficiency. The main question it aims to answer is:
- Will treatment with G-CSF allow improvement in markers of ovarian reserve?

开始日期2023-10-13

申办/合作机构

TRIO Fertility, Inc.初创企业

100 项与 TRIO Fertility, Inc. 相关的临床结果

登录后查看更多信息

0 项与 TRIO Fertility, Inc. 相关的专利（医药）

登录后查看更多信息

项与 TRIO Fertility, Inc. 相关的文献（医药）

2019-04-01·Fertility and Sterility

Why do euploid embryos fail to implant?

作者: R. Smith ; J. Meriano ; R.F. Casper ; D. Nayot

IVIg for recurrent implantation failure: the right treatment for the right patient?

作者: Buckett, William ; Benoit, Joanne ; Mazer, Bruce D. ; Laskin, Carl ; Khoudja, Rabea ; Sylvestre, Camille ; Mahutte, Neal ; Beltempo, Marc ; Genest, Genevieve ; Peero, Einav Kadour ; Banjar, Shorooq ; Phillips, Simon ; Jamal, Wael ; Beauchamp, Coralie ; Ton-leclerc, Shaonie ; Kadoch, Isaac Jacques ; Gold, Phil ; Reinblatt, Shauna ; Dahan, Michael H.

AbstractThe effectiveness of intravenous immunoglobulin (IVIg) for patients with unexplained recurrent implantation failure (uRIF) remains debated. The objective of this study was to evaluate outcomes in patients with uRIF treated with intravenous immunoglobulin (IVIg) compared to a separate cohort of uRIF patients not receiving IVIg within our center. We performed a retrospective cohort study defining uRIF as \(\ge\) 3 unexplained previously failed high quality blastocyst transfer failures in patients with a body mass index < 35, aged < 42, non-smoking, with >7mm type I endometrium at time of transfers. Primary outcomes included live birth, miscarriage, or transfer failure. We documented IVIg side effects and maternal/fetal outcomes. Logistic regression analysis was used to assess for association of IVIg exposure with outcomes and adjust for confounders. The study included 143 patients, with a 2:1 ratio of controls to patients receiving IVIg treatment. The baseline characteristics were similar between groups. There was higher live birth rate (LBR) in patients receiving IVIg (32/49; 65.3%) compared to controls (32/94; 34%); p < 0.001). When stratifying patients into moderate and severe uRIF (respectively 3–4 and \(\ge\) 5 previous good quality blastocyst transfer failures), only patients with severe uRIF benefited from IVIg (LBR (20/29 (69%) versus 5/25 (20%) for controls, p = 0.0004). In the logistic regression analysis, IVIg was associated with a higher odds of live birth (OR 3.64; 95% CI: 1.78–7.67; p = 0.0004). There were no serious adverse events with IVIg. In conclusion, it is reasonable to consider IVIg in well selected patients with \(\ge\) 5 previous unexplained, high quality blastocyst transfer failures. A well-designed randomized controlled trial is needed to confirm these findings.

100 项与 TRIO Fertility, Inc. 相关的药物交易

登录后查看更多信息

100 项与 TRIO Fertility, Inc. 相关的转化医学

登录后查看更多信息